<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04674514</url>
  </required_header>
  <id_info>
    <org_study_id>APG2575MC101</org_study_id>
    <nct_id>NCT04674514</nct_id>
  </id_info>
  <brief_title>APG-2575 Monotherapy or in Combination With Lenalidomide / Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Phase Ib / II Open-Label Stduy of APG-2575 Monotherapy or in Combination With Lenalidomide / Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascentage Pharma Group Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascentage Pharma Group Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability,&#xD;
      efficacy, and PK/ Pharmacodynamics of APG2575 monotherapy or in combination with lenalidomide&#xD;
      (R) and dexamethasone (d) in patients with relapsed/refractory (R/R) multiple myeloma (MM).&#xD;
      The primary objective is to evaluate the safety and tolerability, identify dose-limiting&#xD;
      toxicities (DLT), the maximum tolerated dose (MTD) and the recommended dose (RP2D) of&#xD;
      APG-2575 monotherapy or in combination with Rd in Chinese R/R MM patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability,&#xD;
      efficacy, and PK/ Pharmacodynamics of APG2575 monotherapy or in combination with lenalidomide&#xD;
      (R) and dexamethasone (d) in patients with relapsed/refractory (R/R) multiple myeloma (MM).&#xD;
      The primary objective is to evaluate the safety and tolerability, identify dose-limiting&#xD;
      toxicities (DLT), the maximum tolerated dose (MTD) and the recommended dose (RP2D) of&#xD;
      APG-2575 monotherapy or in combination with Rd in Chinese R/R MM patients.&#xD;
&#xD;
      This study consists of two arms of APG-2575 single agent (arm A) and APG-2575 in combination&#xD;
      with Rd (arm B). All subjects will receive consecutive treatment in 28-day cycles.&#xD;
&#xD;
      All subjects will continue to receive treatment until disease progression, unacceptable&#xD;
      toxicities, or other treatment discontinuation criteria fdefined by the protocol. All&#xD;
      subjects will complete survival follow up after treatment discontinuation until end of the&#xD;
      study, withdrawal of informed consent, loss of follow-up, or death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>28 days</time_frame>
    <description>DLT will be defined based on the rate of drug-related grade 3-5 adverse events experienced within the first 28 days of study treatment. These will be assessed via CTCAE version 5.0.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm A (Single agent)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation APG-2575 at 3 dose levels 3+3 design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (combo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation APG-2575 at 3 dose levels in combination with Rd, 3+3 design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APG-2575</intervention_name>
    <description>APG-2575 orally once daily, every 28 days as a cycle.</description>
    <arm_group_label>Arm A (Single agent)</arm_group_label>
    <arm_group_label>Arm B (combo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rd</intervention_name>
    <description>Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone administered at a dose of 40 mg (or 20 mg for patients&gt;75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle.</description>
    <arm_group_label>Arm B (combo)</arm_group_label>
    <other_name>Lenalidomide +Dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥ 18 years of age;&#xD;
&#xD;
          2. Life expectancy ≥ 6 months;&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) ≤ 2;&#xD;
&#xD;
          4. Corrected QT interval (QTc) based on Frederica or Bazett formula ≤ ≤450ms (male)，or ≤&#xD;
             470ms (female);&#xD;
&#xD;
          5. Patients with Relapsed/Refractory MM, previously treated with at least 1 prior line of&#xD;
             therapy for MM;&#xD;
&#xD;
          6. Symptomatic MM patients with measurable disease (IMWG 2016);&#xD;
&#xD;
          7. Patients with a history of autologous HSCT must have an adequate bone marrow function&#xD;
             and have recovered from any transplant-related toxicity, and meet a minimum of 6&#xD;
             months post-autologous transplant (prior to first dose).&#xD;
&#xD;
          8. Adequate hematologic function without growth factor support&#xD;
&#xD;
          9. Adequate hepatic, renal and coagulation function&#xD;
&#xD;
         10. Male and female subjects of childbearing potential who agree to use highly effective&#xD;
             methods of birth control during the period of therapy and for 90 days after the last&#xD;
             dose of study drug.&#xD;
&#xD;
         11. Ability to understand and voluntarily sign a written informed consent form before&#xD;
             performing any study procedures.&#xD;
&#xD;
         12. Compliance to study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. monoclonal antibody therapy within 8 weeks prior to first dose; CAR-T therapy within 3&#xD;
             months prior to first dose; or other anti-myeloma therapy within 2 weeks prior to&#xD;
             first dose.&#xD;
&#xD;
          2. intolerance to lenalidomide.&#xD;
&#xD;
          3. Plasma cell leukemia, non-secretory multiple myeloma, Fahrenheit macroglobulinemia,&#xD;
             amyloidosis, POEMS syndrome.&#xD;
&#xD;
          4. Subjects planning to undergo a stem cell transplant prior to progression of disease on&#xD;
             this study, i.e., these subjects should not be enrolled in order to reduce disease&#xD;
             burden prior to transplant.&#xD;
&#xD;
          5. Subject has previously received an allogenic stem cell transplant (regardless of&#xD;
             timing).&#xD;
&#xD;
          6. Participant to other clinical trials within 28 days of first dose.&#xD;
&#xD;
          7. Unable to swallow tablets or malabsorption syndrome, disease significantly affecting&#xD;
             gastrointestinal function.&#xD;
&#xD;
          8. Known central nervous system involvement.&#xD;
&#xD;
          9. Failure to have fully recovered (i.e., ≤ Grade 1 toxicity) from the reversible effects&#xD;
             of prior treatment.&#xD;
&#xD;
         10. Not recovered from recent surgical procedures based on investigator's discretion.&#xD;
             Major surgical procedure within ≤28 days or minor surgical procedure within ≤14 days&#xD;
             prior to initiating study treatment, or anticipation of the need for major surgery&#xD;
             during the course of the study treatment and 14 days post last treatment, radiotherapy&#xD;
             ≤14 days.&#xD;
&#xD;
         11. Unstable angina, myocardial infarction, or coronary revascularization within 180 days&#xD;
             prior to the first dose.&#xD;
&#xD;
         12. Active rheumatoid arthritis, active inflammatory bowel disease, or other chronic&#xD;
             inflammatory diseases.&#xD;
&#xD;
         13. Active infection need systemic treatment, including HIV antibody positive, HCV Ab or&#xD;
             RNA more than ULN, or HBV-DNA more than ULN.&#xD;
&#xD;
         14. Severe uncontrollable medical condition, including, but not limited to, symptomatic&#xD;
             congestive heart failure, severe arrhythmias, unstable angina, or a psychiatric&#xD;
             disorder that may affect study adherence;&#xD;
&#xD;
         15. Prior exposure to any BCL-2-directed therapy for MM.&#xD;
&#xD;
         16. Subject has any concurrent or recent malignancy ≤ 5 year prior to registration with&#xD;
             the exception of: basal or squamous cell skin cancer and any carcinoma in situ with&#xD;
             adequate therapy, or other cancers successfully cured with surgical procedures or&#xD;
             drugs ≥ 2 years.&#xD;
&#xD;
         17. Any other condition or circumstance that would, in the opinion of the investigator,&#xD;
             make the patient unsuitable for participation in the study.&#xD;
&#xD;
         18. Female patients who are pregnant or breastfeeding.&#xD;
&#xD;
         19. Requires treatment with a strong cytochrome P450 (CYP) 3A4 inhibitor or inducer、strong&#xD;
             CYP2C8 inhibitor (except study treatment).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yifan Zhai, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Suzhou Yasheng Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Yang</last_name>
    <phone>+86-010-67091790</phone>
    <email>jyang@ascentagepharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wensi Li</last_name>
    <phone>+86-020-28068500</phone>
    <email>wensi.li@ascentagepharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhengzheng Fu, MD.</last_name>
      <phone>+86-0512-67781856</phone>
      <email>fuzhengzheng@suda.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple myeloma</keyword>
  <keyword>Bcl-2 inhibitor</keyword>
  <keyword>APG-2575</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

